Generalized anxiety disorder is characterized by excessive, uncontrollable worry about multiple life domains (finances, health, family, work) occurring more days than not for ≥6 months, accompanied by somatic and cognitive symptoms. [2-3] It affects ~7–8% of primary care patients and is twice as common in women. [3-4] Patients rarely present reporting "worry" — the predominant presentation in primary care and the ED is physical symptoms such as headaches, GI distress, insomnia, and muscle tension. [3]
The following figure from JAMA provides a comprehensive diagnostic and treatment algorithm for anxiety disorders, including GAD:
1. History
- Key screening question: "Do you worry excessively about minor matters?" — an affirmative response is highly suggestive [3]
- Characterize the worry: multifocal (finances, health, family, work, minor matters), excessive, difficult to control [2]
- Duration: symptoms present more days than not for ≥6 months [2]
- Assess for ≥3 of 6 associated symptoms: restlessness/feeling on edge, easy fatigability, difficulty concentrating/mind going blank, irritability, muscle tension, sleep disturbance [2]
- Patients may describe themselves as a lifelong "worrywart" [4]
- Ask about functional impairment: work performance, relationships, daily activities
- Screen for alcohol/substance use as self-medication — ask directly if they use alcohol or drugs to reduce anxiety [3]
- Screen for depression (PHQ-9) and suicidality — 43% lifetime comorbid depression; co-occurrence increases suicide risk [5]
- Assess caffeine intake, energy drink use, and supplement use
2. Alarm Features
- Suicidal ideation or self-harm — GAD is associated with suicidal ideation and attempts [6]
- Comorbid major depression with suicidality — co-occurrence of anxiety + depression increases hospitalization and suicide attempt risk [5]
- Substance use disorder — prevalence ~16.5% in patients with any anxiety disorder [5]
- Atypical features suggesting medical etiology: onset after age 45, vertigo, loss of consciousness, loss of bladder/bowel control, slurred speech, amnesia [2]
- Symptoms suggesting pheochromocytoma: episodic hypertension, headache, diaphoresis, palpitations [2][7]
- Symptoms suggesting hyperthyroidism: heat intolerance, weight loss, tremor, tachycardia [4][7]
- Acute chest pain, severe dyspnea, or syncope requiring cardiac/pulmonary workup
- Psychotic features (hallucinations, delusions) — consider alternative psychiatric diagnoses
3. Medications
First-line (FDA-indicated for GAD)
- Escitalopram (Lexapro): start 5–10 mg, target 10–20 mg daily
- Paroxetine (Paxil): start 10–20 mg, target 20–50 mg daily
- Duloxetine (Cymbalta): start 30 mg, target 60–120 mg daily
- Venlafaxine XR (Effexor XR): start 37.5–75 mg, target 75–225 mg daily [4][8]
Other effective SSRIs (off-label): sertraline, fluoxetine [4]
Second-line/adjunctive
- Buspirone: 5 mg TID, titrate to 15–60 mg/day; no dependence risk [3][9]
- Pregabalin: effective but may cause weight gain and sedation; try antidepressants first [6]
Medications to avoid or use with caution
- Benzodiazepines: not first-line; risk of dependence, withdrawal, rebound anxiety; avoid in patients with alcohol/substance use; never as monotherapy [6][10]
- Quetiapine: efficacious but poorly tolerated; not recommended as first-line [8]
- Bupropion, vortioxetine: inconsistent evidence for GAD; not recommended [3]
Key prescribing pearls
- Start low, go slow — patients with anxiety are sensitive to side effects that can mimic anxiety (jitteriness, palpitations) [5][10]
- Allow 4–6 weeks per dose to assess benefit; full effect may take up to 3 months [4]
- Continue treatment ≥12 months to minimize relapse; discontinuing before 1 year leads to relapse in up to 50% [6][10]
- Taper slowly over weeks when discontinuing to avoid withdrawal [10]
Medications that can cause/worsen anxiety: corticosteroids, sympathomimetics, stimulants, bronchodilators, decongestants, levothyroxine, withdrawal from benzodiazepines/alcohol [4][11]
4. Diet
- Caffeine reduction — caffeine can exacerbate anxiety symptoms; severe anxiety in the context of heavy coffee consumption may represent caffeine-induced anxiety [2]
- Alcohol avoidance — commonly used as self-medication; worsens anxiety long-term and complicates treatment [3]
- Adequate hydration and balanced nutrition support overall well-being
- No specific dietary intervention has strong evidence for GAD, but general healthy eating patterns may support mental health
5. Review of Systems
- Psychiatric: depressed mood, anhedonia (distinguishes MDD from GAD — persistent anhedonia is not a GAD symptom), panic attacks, obsessive thoughts, trauma history, phobias [3]
- Neurologic: headaches, dizziness, tremor, paresthesias, concentration difficulties
- Cardiovascular: palpitations, chest pain, tachycardia
- GI: nausea, abdominal pain, diarrhea, IBS symptoms
- Endocrine: heat/cold intolerance, weight changes, menstrual irregularities
- Respiratory: dyspnea, hyperventilation
- Musculoskeletal: muscle tension, chronic pain, TMJ symptoms
- Sleep: insomnia, restless sleep, early morning awakening
6. Collateral History and Family History
- Family history of anxiety disorders — parental GAD confers HR 3.77 for offspring GAD; heritability estimated at 30–35% [2][10][12]
- Parental history of depression, substance use disorders, or other mental illness increases risk [13-14]
- Collateral from family/partner: functional impairment, behavioral changes, substance use, sleep patterns
- Childhood history: behavioral inhibition, separation anxiety, overprotective parenting [2][11]
- Social context: relationship stressors, financial pressures, occupational demands, social isolation
7. Risk Factors
- Female sex (2–3× more likely) [6]
- Low socioeconomic status [3][13]
- Childhood adversity: physical/sexual abuse, neglect, parental intimate-partner violence, physical punishment [3]
- Parental history of mental disorders [13-14]
- Behavioral inhibition and harm avoidance temperament [2][12]
- Intolerance of uncertainty — relatively specific psychological construct for GAD [3]
- Comorbid psychiatric conditions: depression, other anxiety disorders, substance use disorders [5]
- Chronic medical conditions: chronic pain, cardiovascular disease, diabetes, COPD, IBS [15]
- Smoking and alcohol use [13]
- Stressful life events in childhood and adulthood [14]
- Marital status: widowed or divorced [13]
8. Differential Diagnosis
Psychiatric mimics
- Major depressive disorder — significant symptom overlap; distinguish by persistent anhedonia (characteristic of MDD, not GAD) [3]
- Panic disorder — recurrent unexpected panic attacks with sudden onset; GAD worry-triggered panic attacks do not qualify [2]
- Social anxiety disorder — fear focused on social/performance situations and evaluation by others [2]
- PTSD — temporally linked to traumatic event with reexperiencing symptoms [4]
- OCD — intrusive unwanted thoughts/urges vs. GAD's future-oriented worry [2]
- Illness anxiety disorder/somatic symptom disorder — worry focused exclusively on health [2]
- Bipolar disorder (manic/hypomanic episodes) [6]
- Substance use disorder — anxiety only in context of intoxication/withdrawal [2]
Medical mimics (cannot-miss)
- Hyperthyroidism — heat intolerance, weight loss, tremor, tachycardia [2][7]
- Pheochromocytoma — episodic hypertension, headache, diaphoresis [2][7]
- Cardiac arrhythmias (SVT, atrial fibrillation) — palpitations, dyspnea [2]
- Pulmonary embolism — acute dyspnea, chest pain, tachycardia [2]
- Hypoglycemia — tremor, diaphoresis, palpitations [2]
- Substance/medication-induced anxiety — stimulants, cocaine, cannabis, alcohol/benzodiazepine withdrawal [2][11]
9. Past Medical History
- Prior anxiety episodes and treatment response (assess adequacy of prior trials — dose, duration, premature discontinuation) [5]
- History of depression, bipolar disorder, PTSD, or other psychiatric conditions
- Substance use history (alcohol, cannabis, stimulants, benzodiazepines)
- Chronic medical conditions: thyroid disease, cardiac disease, COPD, chronic pain, IBS, diabetes [15]
- Surgical history (particularly thyroid, cardiac)
- Prior psychiatric hospitalizations or suicide attempts
- Medication history including prior psychotropic trials and responses
10. Physical Exam
Vital signs
- Tachycardia, elevated blood pressure (may be situational or suggest medical etiology)
- Tachypnea/hyperventilation
Focused exam
- Thyroid: palpate for enlargement or nodules; assess for proptosis, lid lag [4]
- Cardiovascular: irregular rhythm, murmurs (rule out arrhythmia, valvular disease) [7]
- Neurologic: tremor, hyperreflexia (hyperthyroidism), focal deficits
- General: diaphoresis, restlessness, psychomotor agitation
- Musculoskeletal: muscle tension (especially trapezius, jaw/TMJ)
- Skin: warm/moist skin (hyperthyroidism), diaphoresis
- Mental status: anxious affect, pressured speech, intact cognition; assess for psychosis
11. Lab Studies
Laboratory testing is not routine for a straightforward GAD presentation but should be guided by clinical suspicion for medical mimics: [4][11]
- TSH (± free T4) — rule out hyperthyroidism; consider in all new presentations [4]
- CBC — screen for anemia, infection
- CMP — electrolytes, glucose (hypoglycemia), renal/hepatic function (relevant for medication selection)
- Urine drug screen — if substance use suspected [4]
- Serum calcium — hyperparathyroidism can mimic anxiety [2]
- Vitamin B12 — deficiency associated with anxiety symptoms [2]
- If pheochromocytoma suspected: plasma-fractionated metanephrines [7]
Monitoring on treatment: hepatic function if starting duloxetine; metabolic parameters as clinically indicated
12. Imaging
- Not routinely indicated for GAD diagnosis
- Chest X-ray if pulmonary symptoms warrant evaluation
- CT/MRI brain only if neurologic findings suggest structural pathology (new-onset seizures, focal deficits)
- Echocardiography if cardiac murmur or structural heart disease suspected
- Thyroid ultrasound if thyroid nodule palpated on exam
- Imaging for pheochromocytoma (CT/MRI abdomen) only if biochemical testing is positive
13. Special Tests
Screening and severity tools
- GAD-7 (Generalized Anxiety Disorder 7-item scale) — validated screening tool; sensitivity 60.6–89%, specificity 82–87.6% [5]
- Scores: 0–4 minimal, 5–9 mild, 10–14 moderate, ≥15 severe
- Use serially (monthly) to track treatment response; ≥50% reduction indicates response [3]
- GAD-2 — 2-item rapid screen; useful for initial triage [6]
- PHQ-9 — screen for comorbid depression (essential in all GAD evaluations)
- Columbia Suicide Severity Rating Scale (C-SSRS) — if suicidality suspected
- AUDIT/DAST — screen for alcohol/substance use disorders
14. ECG
- Indicated when patients present with palpitations, chest pain, tachycardia, or syncope to rule out arrhythmia [4-5]
- Rule out atrial fibrillation, SVT, prolonged QTc (relevant before starting certain SSRIs)
- Consider Holter monitor if intermittent palpitations with normal resting ECG [2]
- Baseline ECG may be prudent before starting medications that can prolong QTc (e.g., escitalopram at higher doses, citalopram)
15. Assessment
Severity stratification (GAD-7 based)
- Mild (5–9): may respond to psychoeducation, lifestyle modifications, and/or brief behavioral interventions alone
- Moderate (10–14): pharmacotherapy and/or CBT recommended
- Severe (≥15): combined pharmacotherapy + psychotherapy; consider psychiatry referral
Typical presentation: chronic, pervasive worry about everyday matters with insomnia, muscle tension, fatigue, and GI symptoms; often presents to primary care with somatic complaints rather than reporting anxiety [3]
Atypical presentations to recognize: predominantly somatic (headache, GI distress, chronic pain), late-onset (>45 years — higher suspicion for medical etiology), children presenting with recurrent abdominal pain and school avoidance [2-3]
Complications: comorbid MDD (43%), alcohol/substance use disorders (~16.5%), increased cardiovascular morbidity, functional disability, and suicide risk [5][15-16]
16. Treatment Plan
Initial stabilization (ED/acute setting)
- Reassurance and psychoeducation about the nature of anxiety
- Address acute distress with calm environment, supportive care
- Avoid initiating benzodiazepines if possible; if used acutely, limit to short course with clear plan
Outpatient management (mainstay)
Psychoeducation (first step in all cases):
- Educate about GAD as a treatable medical condition; normalize symptoms [5]
- Lifestyle modifications: regular exercise (evidence supports benefit), sleep hygiene, caffeine reduction, alcohol avoidance [3]
Pharmacotherapy:
- First-line: SSRI or SNRI — escitalopram, sertraline, duloxetine, or venlafaxine XR [4-5]
- Start at low dose, titrate every 4–6 weeks; allow at least moderate dose before deeming ineffective [4]
- If first SSRI/SNRI fails after adequate trial → switch to a different SSRI/SNRI [4]
- Second-line: buspirone (adjunctive or monotherapy), pregabalin [3]
Psychotherapy:
- CBT is the most effective and well-studied psychotherapy for GAD [6][9]
- Can be used alone (mild-moderate) or combined with pharmacotherapy (moderate-severe)
- Exposure-based strategies should be integrated into treatment [5]
Combined treatment:
The following flowchart from JAMA Internal Medicine outlines the clinical algorithm for anxiety treatment in primary care:
17. Disposition
Discharge (vast majority)
- Most GAD patients are managed entirely as outpatients
- Safe for discharge if no suicidality, no acute medical emergency, and able to follow up
Admission criteria
- Active suicidal ideation with plan or intent
- Comorbid severe depression with safety concerns
- Severe functional impairment (unable to care for self)
- Need for medically supervised detoxification (comorbid substance withdrawal)
- Acute medical condition requiring inpatient workup (e.g., new arrhythmia, suspected pheochromocytoma)
Specialist consultation triggers
- Treatment-refractory GAD (failure of ≥2 adequate SSRI/SNRI trials) → psychiatry [3]
- Complex comorbidity (bipolar disorder, psychosis, severe substance use disorder) → psychiatry
- If <50% improvement in GAD-7 after 3 months of treatment → consider referral [3]
- Suspected medical etiology → appropriate specialist (endocrinology, cardiology)
18. Follow Up / Return Precautions
Follow-up timing
- 2–4 weeks after initiating or changing medication to assess tolerability and early response [4]
- Serial GAD-7 monthly to track symptom trajectory [4]
- Reassess at 4–6 weeks per dose level; further titration if partial response [4]
- After stabilization: follow-up every 1–3 months
Return precautions (counsel patients)
- Worsening anxiety, new panic attacks, or inability to function
- Suicidal thoughts or self-harm urges — seek immediate care
- Medication side effects: severe nausea, agitation, insomnia, serotonin syndrome symptoms (fever, rigidity, myoclonus)
- New physical symptoms: chest pain, syncope, severe headache
Patient counseling points
- SSRIs/SNRIs take 2–4 weeks to begin working; full benefit may take months [4-5]
- Early side effects (nausea, jitteriness) often improve within weeks [4]
- Do not stop medication abruptly — taper under medical guidance [10]
- Avoid alcohol as self-medication [3]
- Regular exercise, sleep hygiene, and caffeine reduction are evidence-supported adjuncts [3]
Expected recovery course: GAD is a chronic condition; most patients improve significantly with treatment, but relapse is common. Long-term management with medication (≥12 months) and/or ongoing CBT skills practice is typically needed. [6][10]
References
1. Diagnostic and Statistical Manual of Mental Disorders. — Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al American Psychiatric Association (2022). 2022.
2. Generalized Anxiety Disorder. — Stein MB, Sareen J. The New England Journal of Medicine. 2015.
3. Treatment of Anxiety for Adults in Primary Care Settings. — Shepardson RL, Khan JS, Buckheit KA, Funderburk JS. JAMA Internal Medicine. 2026.
4. Anxiety Disorders: A Review. — Szuhany KL, Simon NM. The Journal of the American Medical Association. 2022.
5. Generalized Anxiety Disorder and Panic Disorder in Adults. — DeGeorge KC, Grover M, Streeter GS. American Family Physician. 2022.
6. Anxiety Disorders in Children and Adolescents. — Kowalchuk A, Gonzalez SJ, Zoorob RJ. American Family Physician. 2022.
7. Pharmacological Treatments for Generalised Anxiety Disorder: A Systematic Review and Network Meta-Analysis. — Slee A, Nazareth I, Bondaronek P, et al. Lancet. 2019.
8. Anxiety Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. — O'Connor EA, Henninger ML, Perdue LA, et al. The Journal of the American Medical Association. 2023.
9. Anxiety Disorders. — Penninx BW, Pine DS, Holmes EA, Reif A. Lancet. 2021.
10. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. — Walter HJ, Bukstein OG, Abright AR, et al. Journal of the American Academy of Child and Adolescent Psychiatry. 2020.
11. Incidence and Risk Patterns of Anxiety and Depressive Disorders and Categorization of Generalized Anxiety Disorder. — Beesdo K, Pine DS, Lieb R, Wittchen HU. Archives of General Psychiatry. 2010.
12. Screening for Anxiety Disorders in Adults: US Preventive Services Task Force Recommendation Statement. — US Preventive Services Task Force, Barry MJ, Nicholson WK, et al. The Journal of the American Medical Association. 2023.
13. Risk Factors for the Onset of Panic and Generalised Anxiety Disorders in the General Adult Population: A Systematic Review of Cohort Studies. — Moreno-Peral P, Conejo-Cerón S, Motrico E, et al. Journal of Affective Disorders. 2014.
14. Generalized Anxiety Disorder and Medical Illness. — Culpepper L. The Journal of Clinical Psychiatry. 2009.
15. Generalized Anxiety Disorder. — DeMartini J, Patel G, Fancher TL. Annals of Internal Medicine. 2019.